Status:
UNKNOWN
Impact of a Systematic Palliative Care on Quality of Life, in Advanced Idiopathic Pulmonary Fibrosis.
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Idiopathic Pulmonary Fibrosis
Eligibility:
All Genders
41+ years
Phase:
NA
Brief Summary
Idiopathic pulmonary fibrosis (IPF) is a rare and severe disease with a survival median between 2 and 4 years which leads to a profound alteration of the quality of life. In thoracic oncology, the sy...
Detailed Description
Idiopathic pulmonary fibrosis (IPF) is a rare and severe disease with a survival median between 2 and 4 years which leads to a profound alteration of the quality of life. This alteration results from ...
Eligibility Criteria
Inclusion
- Age\> 40 years
- Patient with confirmed diagnosis of IPF according to the American Thoracic Society (ATS) / European Respiratory Society (ERS) / Japanese Respiratory Society (JRS) / Latin American Thoracic Association (ALAT) criteria. The patient may be included regardless of the date of diagnosis.
- Advanced IPF with Forced Vital Capacity (FVC) \<50%" of predicted value and / or Diffusing capacity for carbon monoxide ((DLCO) \<30% of predicted value or inability to achieve the Functional Respiratory Investigations (EFR) due to respiratory severity. EFR dated less than 3 months.
- Absence of argument for acute or subacute exacerbation in the last 6 months.
- Patient who can be followed in ambulatory consultation/ outpatient consultation.
- Informed consent signed (signed by the patient or in the presence of a third party for patients who are poorly fluent in French).
- Affiliation to the social security system.
Exclusion
- Patient unable to respond to quality of life questionnaires.
- Inability (physical or mental) to give a written informed consent.
- Acute exacerbation of fibrosis in the previous 6 months.
- Patient eligible for a pulmonary transplant.
- Participation in other therapeutic trial
- Patient cannot be followed in ambulatory consultation.
- Patient under trustee
Key Trial Info
Start Date :
December 4 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2021
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT03229343
Start Date
December 4 2017
End Date
February 1 2021
Last Update
January 26 2018
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Robert Ballanger
Aulnay-sous-Bois, France, 93602
2
Hôpital Avicenne
Bobigny, France, 93000
3
Centre Hospitalier de Versailles Andre Mignot
Le Chesnay, France, 78150
4
Hôpital LOUIS PRADEL
Lyon, France, 69677